Education
About Us
Working with TipRanks
Follow Us
Medicinova (MNOV)
:MNOV
MNOV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.12 - $2.55
Previous CloseN/A
Volume15.80K
Average Volume (3M)16.41K
Market Cap
$73.08M
Enterprise ValueN/A
Total Cash (Recent Filing)$62.31M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.46
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding49,046,246
10 Day Avg. Volume11,781
30 Day Avg. Volume16,413
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)87.06
Price to Cash Flow (P/CF)-9.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$9.00Price Target Upside512.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Ownership Overview
2.88%
Insiders
2.53% Mutual Funds
2.61% Other Institutional Investors
90.48% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MNOV FAQ
What was Medicinova’s price range in the past 12 months?
Medicinova lowest stock price was $1.12 and its highest was $2.55 in the past 12 months.
What is Medicinova’s market cap?
Medicinova’s market cap is $73.08M.
When is Medicinova’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Medicinova’s earnings last quarter?
Medicinova released its earnings results on Jul 27, 2022. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.087 by -$0.063.
Is Medicinova overvalued?
According to Wall Street analysts Medicinova’s price is currently Undervalued.
Does Medicinova pay dividends?
Medicinova does not currently pay dividends.
What is Medicinova’s EPS estimate?
Medicinova’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medicinova have?
Medicinova has 49,046,246 shares outstanding.
What happened to Medicinova’s price movement after its last earnings report?
Medicinova reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.087. Following the earnings report the stock price went down -1.835%.
Which hedge fund is a major shareholder of Medicinova?
Currently, no hedge funds are holding shares in MNOV
---
Medicinova Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (512.24% Upside)
$9.00 (512.24% Upside)
Blogger Sentiment
Bullish
MNOV Sentiment 70%
Sector Average 69%
Sector Average 69%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.52%
12-Months-Change
Fundamentals
Return on Equity
-19.24%
Trailing 12-Months
Asset Growth
-15.68%
Trailing 12-Months
Company Description
Medicinova
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
---
MNOV Stock 12 Month Forecast
Average Price Target
$9.00
▲(512.24% Upside)
Technical Analysis
Best Analysts Covering MNOV
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-37.30%
initiated a buy rating 4 months ago
Copying Jason Kolbert's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -37.30% per trade.
---